Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

Gastroenterology, 2024

Northwestern University, Icahn School of Medicine at Mount Sinai, University Hospital Schleswig-Holstein, University of Lübeck, Vita-Salute San Raffaele University, Nicolaus Copernicus University, Children's Memorial Health Institute, National University Zaporizhzhia Polytechnic, National Academy of Medicine, Academic Center of Medicine, Międzyleski Szpital Specjalistyczny w Warszawie, Kliničko Bolnički Centar Zvezdara, Research Institute of Fundamental and Clinical Immunology, Sheba Medical Center, Sopot University of Applied Science, Università Cattolica del Sacro Cuore, Siberian Research and Technological Institute for Processing Agricultural Products, Klinički bolnički centar Osijek, University of Osijek, Centrum Leczenia Oparzeń, Pyatigorsk Oncology Center, Pyatigorsk State University, Saint-Petersburg Medico-Social Institute, Celltrion (South Korea), UC San Diego Health System, University of California San Diego

View Free PDF Publisher Website

An abstract is not available for this record. Please visit the publisher website for more details.

Citations